← FDA DRUG APPROVALS

FDA ANDA · ANDA077007

FOSTER AND THRIVE NICOTINE

nicotine polacrilex

Sponsor: PERRIGO R AND D

APPLICATION
ANDA077007
TYPE
ANDA
ORIGINAL APPROVAL
2006-01-31
LATEST ACTION
2025-04-01
ROUTE
ORAL
DOSAGE FORM
TROCHE/LOZENGE
MARKETING STATUS
Over-the-counter

Products

NICOTINE POLACRILEXOver-the-counter
NICOTINE POLACRILEX EQ 2MG BASE · TROCHE/LOZENGE · ORAL
NICOTINE POLACRILEXOver-the-counter
NICOTINE POLACRILEX EQ 4MG BASE · TROCHE/LOZENGE · ORAL

Approval history

2025-04-01Manufacturing (CMC) · Supplement 55 · unknownAP
2024-07-12Manufacturing (CMC) · Supplement 51 · unknownAP
2016-06-19Labeling · Supplement 34 · standardAP
2015-04-03Labeling · Supplement 28 · standardAP
2014-11-03Labeling · Supplement 23 · standardAP
2014-10-22Manufacturing (CMC) · Supplement 24 · unknownAP
2008-04-14Labeling · Supplement 10AP
2006-01-31OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →